Tag
Ivosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing crit
The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.
